-
公开(公告)号：EP3886896A1
公开(公告)日：2021-10-06
申请号：EP19813465.2
申请日：2019-11-28
-
2.发明公开GP41 PEPTIDES AND METHODS BASED-THEREON FOR INHIBITING HIV FUSION TO TARGET CELLS 审中-公开GP41肽和基于事实的过程抑制HIV的合并与靶细胞
公开(公告)号：EP1521587A2
公开(公告)日：2005-04-13
申请号：EP03741908.2
申请日：2003-06-10
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16122
摘要： The present invention provides peptides which are based on the HIV GP41 protein and have inhibitory activity against the fusion of HIV virus to its target cells. The invention also provides therapeutic methods based on the administration of the peptides of the invention to a subject infected with the HIV virus.
-
公开(公告)号：EP1991564A2
公开(公告)日：2008-11-19
申请号：EP07733909.1
申请日：2007-03-02
申请人： Mymetics Corporation , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Pevion Biotech LTD.
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/0043 , A61K9/127 , A61K9/1271 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , A61K2039/6018 , A61K2039/6075 , C07K14/005 , C12N2740/16122 , C12N2740/16134
摘要： The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein of a human immunodeficiency virus (HIV).
-
公开(公告)号：EP1991564B1
公开(公告)日：2013-09-11
申请号：EP07733909.1
申请日：2007-03-02
申请人： Mymetics Corporation , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Pevion Biotech Ltd.
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/0043 , A61K9/127 , A61K9/1271 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , A61K2039/6018 , A61K2039/6075 , C07K14/005 , C12N2740/16122 , C12N2740/16134
-
公开(公告)号：EP2393509A1
公开(公告)日：2011-12-14
申请号：EP10702704.7
申请日：2010-02-08
发明人： FLEURY, Sylvain , BOMSEL, Morgane
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5258 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/55555 , A61K2039/575 , A61K2039/6018 , C07K2319/40 , C12N2740/15022 , C12N2740/16122 , C12N2740/16134 , C12N2760/16142
摘要： The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising : a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.
摘要翻译： 本发明涉及用于HIV的治疗或预防性治疗的方法，特别是一种预防性疫苗方法，其至少包括：向患者施用包含gp41的膜近端胞外域（MPER）的广泛中和表位的第一抗原， 并且向相同的患者施用包含修饰的多肽的第二抗原，所述修饰的多肽包含由式NLC表示的三个连续区段N，L和C，并且包含：gp41（N）的N-螺旋区域，gp41的C-螺旋区域（C ）和连接环，其包含在N和C-螺旋之间的合成接头（L），所述接头代替gp41的氨基酸593-617，编号方案基于原型分离物HIV-1 HxB2进化枝B菌株，所述 多肽包含犊牛素-1中和和98.6D表位，而不是2F5和4E10表位，而不是融合肽，该多肽与人白细胞介素2具有最小的免疫原性交叉反应性。
-
公开(公告)号：EP2393510A1
公开(公告)日：2011-12-14
申请号：EP10703186.6
申请日：2010-02-08
申请人： Mymetics Corporation
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5258 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/55555 , A61K2039/575 , C12N2740/15022 , C12N2740/16122 , C12N2740/16134
摘要： The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising : a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593- 617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2).
摘要翻译： 本发明涉及包含由NLC表示的三个连续片段N，L和C的修饰多肽，其包含：gp41（N）的N-螺旋区，gp41（C）的C-螺旋区，以及连接 所述多肽包含在N和C-螺旋之间的合成接头（L），所述接头代替gp41的氨基酸593-617，编号方案基于原型分离物HIV-1 HxB2进化枝B菌株，所述多肽包含小牛血清素， 1个中和和98.6 D表位，而不是2F5和4E10表位，而不是融合肽，该多肽与人白细胞介素2（IL2）具有最小的免疫原性交叉反应性。
-
7.发明公开ANTIBODY OR A FRAGMENT THEREOF, HAVING NEUTRALIZING ACTIVITY AGAINST HIV BUT NOT AGAINST IL2 审中-公开抗体或WITH中和活性的抗HIV或其片段但不反对IL2
公开(公告)号：EP1879617A1
公开(公告)日：2008-01-23
申请号：EP05737951.3
申请日：2005-05-02
发明人： BOMSEL, Morgane , TUDOR, Daniela
CPC分类号： C07K16/1063 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565
摘要： The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof.
-
公开(公告)号：EP1680444A1
公开(公告)日：2006-07-19
申请号：EP04744087.0
申请日：2004-07-29
申请人： Mymetics Corporation
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/57 , C07K2319/00 , C12N2740/16122 , C12N2740/16134
摘要： The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: - a size convenient for keeping the native conformation of the interaction between N- and C-helices, and - an hydrophily sufficient to provide a soluble and stable trimeric form to said modified polypeptide.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.01 秒)
